Glenmark receives USFDA tentative approval for Apremilast Tablets
Capital MarketGlenmark Pharmaceuticals has received the United States Food & Drug
Administration's (USFDA) tentative approval for Apremilast Tablets, 10 mg, 20 mg and 30 mg, the generic version of Otezla Tablets, 10 mg, 20 mg and 30 mg, of Amgen, Inc.
The Otezla Tablets, 10 mg, 20 mg and 30 mg market achieved annual sales of approximately $2.7 billion.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
